HeimMRK • NYSE
add
Merck & Co Inc
97,45 $
Eftir lokun(0,00%)0,00
97,45 $
Lokað: 28. jan., 16:41:20 GMT-5 · USD · NYSE · Lagalegir fyrirvarar
Við síðustu lokun
97,95 $
Dagbil
96,59 $ - 98,88 $
Árabil
94,48 $ - 134,63 $
Markaðsvirði
246,51 ma. USD
Meðalmagn
11,07 m.
V/H-hlutf.
20,44
A/V-hlutfall
3,32%
Aðalkauphöll
NYSE
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 16,66 ma. | 4,35% |
Rekstrarkostnaður | 8,40 ma. | 48,81% |
Nettótekjur | 3,16 ma. | -33,47% |
Hagnaðarhlutfall | 18,95 | -36,26% |
Hagnaður á hvern hlut | 1,57 | -26,29% |
EBITDA | 5,51 ma. | -21,97% |
Virkt skatthlutfall | 22,71% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 14,59 ma. | 66,34% |
Heildareignir | 117,53 ma. | 10,12% |
Heildarskuldir | 72,97 ma. | 11,53% |
Eigið fé alls | 44,56 ma. | — |
Útistandandi hlutabréf | 2,53 ma. | — |
Eiginfjárgengi | 5,57 | — |
Arðsemi eigna | 9,48% | — |
Ávöxtun eigin fjár | 13,29% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | 3,16 ma. | -33,47% |
Handbært fé frá rekstri | 9,29 ma. | 20,40% |
Reiðufé frá fjárfestingum | -3,84 ma. | -1.051,20% |
Reiðufé frá fjármögnun | -2,42 ma. | 43,20% |
Breyting á handbæru fé | 3,32 ma. | 12,11% |
Frjálst peningaflæði | 7,42 ma. | 28,97% |
Um
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of which it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.
Merck & Co. was originally established as the American affiliate of Merck Group in 1891. Merck develops and produces medicines, vaccines, biologic therapies and animal health products. It has several blockbuster products, including cancer immunotherapy, anti-diabetic medications, and vaccines for HPV and chickenpox, each generating significant revenue as of 2020.
The company is ranked 71st on the 2022 Fortune 500 and 87th on the 2022 Forbes Global 2000, both based on 2021 revenues. In 2023, the company’s seat in Forbes Global 2000 was 73. Wikipedia
Framkvæmdastjóri
Stofnsett
1. jan. 1891
Vefsvæði
Starfsfólk
71.000
